Tesla Motors Inc (NASDAQ:TSLA) is down over nearly 4% in early trading after the company reported lower than expected vehicle deliveries for Q2. The electric-car maker delivered 14,370 vehicles compared to its 17,000 target due to low production levels at the beginning of the quarter.. The company also missed its delivery target last quarter, delivering 14,810 cars compared to its 16,000 delivery target. The company is working towards increasing its production capacity, producing 2,000 more vehicles than last quarter. However, 5,150 of the produced vehicles were in transit and will be delivered to customers in the third quarter.

Despite this delivery miss, analyst Ben Kallo of Baird reiterated an Outperform rating on the company with a $33 price target. He states, “Total Q2 deliveries were below our estimate and FY:16 deliveries are expected to be slightly below TSLA’s previously guided range. That said, TSLA had >5k vehicles in transit at quarter-end, and significantly ramped production, nearly reaching its targeted production rate of ~2k vehicles per week. We would be buyers on any weakness as upcoming catalysts (additional Model III details, cash flow positive, Model X reviews, gigafactory updates) should drive shares higher over the long term.”

According to TipRanks, out of the 21 analysts who have rated the stock in the last 3 months, 8 gave a Buy rating, 5 gave a Sell rating, and 5 remain on the sidelines. The average 12-month price target for the stock is $267.39, marking a 23% upside from where shares last closed.

Amedica Corporation (NASDAQ:AMDA) is down 20% after the company announced the pricing of an $11 million public offering. The company will sell 3.608 million class A units for $1 per unit and 7.392 million Class B units for $1,000 per unit, comprised of one share of preferred stock which is convertible into 1,000 shares of common stock and 1,000 warrants. The conversion price of preferred stock remains fixed and does not have dividend right. The offer is expected to close on July 8, 2016.

According to TipRanks, only 1 financial blogger rated the company in the past 3 months with a bearish rating.

Insys Therapeutics Inc (NASDAQ:INSY) is up 18% in pre-market trading after announcing FDA approval of Syndros, an orally administered cannabinoid dronabinol drug. The drug is used to treat anorexia resulting from weight loss in AIDS patients and nausea in chemotherapy patients who have not adequately responded to conventional treatments. Syndros is awaiting scheduling by the U.S Drug Enforcement Administration. The company plans on launching Syndros in the second half of 2016.

According to TipRanks, out of the 4 analysts who have rated the stock in the last 3 months, 3 gave a Buy rating while 1 remains neutral. The average 12-month price target for htes tock is $22.33, marking a 66% upside from where shares last closed.

Seadrill Ltd (NYSE:SDRL) is falling 4% in pre-market trading after a more than 2% decrease in crude oil prices. Brent crude oil fell $1.20 to $48.90 a barrel this morning due to continuing concerns regarding slowing economic growth following the Brexit. This slow economic growth is spurring demand concerns from investors, especially as China is set to release data showing weakness in trade and investment. According to a Barclay’s report, “The deterioration in the global economic outlook, financial market uncertainty and ripple effects on key areas of oil demand growth are likely to exacerbate already-lackluster industrial demand growth trends.”

According to TipRanks’ statistics, out of the 4 analysts who have rated the company in the past 3 months, 3 gave a Sell rating and 1 remains on the sidelines. The average 12-month price target for the stock is $1.90, marking a 44% downside from where shares last closed.